Chinitz Larry A, El-Chami Mikhael F, Sagi Venkata, Garcia Hector, Hackett F Kevin, Leal Miguel, Whalen Patrick, Henrikson Charles A, Greenspon Arnold J, Sheldon Todd, Stromberg Kurt, Wood Nicole, Fagan Dedra H, Sun Chan Joseph Yat
NYU Langone Medical Center, New York, New York.
Emory University Medical Center, Atlanta, Georgia.
Heart Rhythm. 2023 Jan;20(1):46-54. doi: 10.1016/j.hrthm.2022.08.033. Epub 2022 Sep 6.
Previous studies demonstrated that accelerometer-based, mechanically timed atrioventricular synchrony (AVS) is feasible using a leadless ventricular pacemaker.
The purpose of this study was to determine the performance of a leadless ventricular pacemaker with accelerometer-based algorithms that provide AVS pacing.
AccelAV was a prospective, single-arm study to characterize AVS in patients implanted with a Micra AV, which uses the device accelerometer to mechanically detect atrial contractions and promote VDD pacing. The primary objective was to characterize resting AVS at 1 month in patients with complete atrioventricular block (AVB) and normal sinus function.
A total of 152 patients (age 77 ± 11 years; 48% female) from 20 centers were enrolled and implanted with a leadless pacemaker. Among patients with normal sinus function and complete AVB (n = 54), mean resting AVS was 85.4% at 1 month, and ambulatory AVS was 74.8%. In the subset of patients (n = 20) with programming optimization, mean ambulatory AVS was 82.6%, representing a 10.5% improvement (P <.001). Quality of life as measured by the EQ-5D-3L (EuroQol Five-Dimensions Three-Level questionnaire) improved significantly from preimplant to 3 months (P = .031). In 37 patients with AVB at both 1 and 3 months, mean AVS during rest did not differ (86.1% vs 84.1%; P = .43). There were no upgrades to dual-chamber devices or cardiac resynchronization therapy through 3 months.
Accelerometer-based mechanical atrial sensing provided by a leadless pacemaker implanted in the right ventricle significantly improves quality of life in a select cohort of patients with AV block and normal sinus function. AVS remained stable through 3 months, and there were no system upgrades to dual-chamber pacemakers.
先前的研究表明,使用无导线心室起搏器基于加速度计进行机械定时的房室同步(AVS)是可行的。
本研究的目的是确定具有基于加速度计算法以提供AVS起搏功能的无导线心室起搏器的性能。
AccelAV是一项前瞻性单臂研究,旨在对植入Micra AV的患者的AVS进行特征描述,该设备使用设备加速度计来机械检测心房收缩并促进VDD起搏。主要目标是对完全性房室传导阻滞(AVB)且窦性功能正常的患者在1个月时的静息AVS进行特征描述。
来自20个中心的152例患者(年龄77±11岁;48%为女性)入组并植入了无导线起搏器。在窦性功能正常且完全性AVB的患者(n = 54)中,1个月时静息AVS的平均值为85.4%,动态AVS为74.8%。在进行了程控优化的患者亚组(n = 20)中,动态AVS的平均值为82.6%,提高了10.5%(P <.001)。通过EQ-5D-3L(欧洲五维度三级问卷)测量的生活质量从植入前到3个月有显著改善(P =.031)。在1个月和3个月时均存在AVB的37例患者中,静息时的平均AVS无差异(86.1%对84.1%;P =.43)。在3个月内没有升级为双腔设备或心脏再同步治疗的情况。
植入右心室的无导线起搏器基于加速度计的机械心房感知功能在特定的AV阻滞且窦性功能正常的患者队列中显著改善了生活质量。AVS在3个月内保持稳定,且没有系统升级为双腔起搏器。